159 related articles for article (PubMed ID: 33817853)
21. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
[TBL] [Abstract][Full Text] [Related]
22. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
[TBL] [Abstract][Full Text] [Related]
23. Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.
Tse CS; Loftus EV; Raffals LE; Gossard AA; Lightner AL
Aliment Pharmacol Ther; 2018 Jul; 48(2):190-195. PubMed ID: 29808485
[TBL] [Abstract][Full Text] [Related]
24. Antibodies against infliximab are associated with de novo development of antibodies to adalimumab and therapeutic failure in infliximab-to-adalimumab switchers with IBD.
Frederiksen MT; Ainsworth MA; Brynskov J; Thomsen OO; Bendtzen K; Steenholdt C
Inflamm Bowel Dis; 2014 Oct; 20(10):1714-21. PubMed ID: 25069030
[TBL] [Abstract][Full Text] [Related]
25. Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases.
Stevens BW; Borren NZ; Velonias G; Conway G; Cleland T; Andrews E; Khalili H; Garber JG; Xavier RJ; Yajnik V; Ananthakrishnan AN
Dig Dis Sci; 2017 Jan; 62(1):197-206. PubMed ID: 27796768
[TBL] [Abstract][Full Text] [Related]
26. [Biological drugs in inflammatory bowel disease: Management and care].
Guerra I; Bermejo F
Rev Esp Enferm Dig; 2015 Jul; 107(7):454. PubMed ID: 26140643
[No Abstract] [Full Text] [Related]
27. So many therapies-So little data: How to choose? Session two summary.
Begun J
J Gastroenterol Hepatol; 2021 Apr; 36 Suppl 1():14-15. PubMed ID: 33817855
[No Abstract] [Full Text] [Related]
28. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues.
Caviglia R; Boskoski I; Cicala M
Expert Opin Drug Saf; 2008 Sep; 7(5):617-32. PubMed ID: 18759714
[TBL] [Abstract][Full Text] [Related]
29. [Biosimilars in inflamatory bowel disease: Management and care].
Guerra I; Bermejo F
Rev Esp Enferm Dig; 2015 Jun; 107(6):389. PubMed ID: 26031872
[No Abstract] [Full Text] [Related]
30. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
31. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
Shen H; Lipka S; Katz S
J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
[No Abstract] [Full Text] [Related]
32. Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease.
Prieto-Pérez R; Almoguera B; Cabaleiro T; Hakonarson H; Abad-Santos F
Int J Mol Sci; 2016 Feb; 17(2):225. PubMed ID: 26861312
[TBL] [Abstract][Full Text] [Related]
33. Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD).
Porcari S; Viola A; Orlando A; Privitera AC; Ferracane C; Cappello M; Vitello A; Siringo S; Inserra G; Magnano A; Mocciaro F; Di Mitri R; Belluardo N; Fidanza O; Garufi S; Magrì G; Bertolami C; Carroccio A; Macaluso FS; Renna S; Ventimiglia M; Alibrandi A; Cottone M; Fries W;
Drugs Aging; 2020 May; 37(5):383-392. PubMed ID: 32016824
[TBL] [Abstract][Full Text] [Related]
34. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
Chang JT; Lichtenstein GR
Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
[TBL] [Abstract][Full Text] [Related]
35. [Biological therapy in women with inflammatory bowel disease during pregnancy].
Koželuhová J; Balihar K; Janská E; Fremundová L; Matějovič M
Vnitr Lek; 2014; 60(7-8):630-4. PubMed ID: 25130641
[TBL] [Abstract][Full Text] [Related]
36. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure.
Zelinkova Z; van der Ent C; Bruin KF; van Baalen O; Vermeulen HG; Smalbraak HJ; Ouwendijk RJ; Hoek AC; van der Werf SD; Kuipers EJ; van der Woude CJ;
Clin Gastroenterol Hepatol; 2013 Mar; 11(3):318-21. PubMed ID: 23103819
[TBL] [Abstract][Full Text] [Related]
37. Prior Antibodies to Infliximab or Adalimumab Are Related to Immunogenicity to Vedolizumab in Patients With Inflammatory Bowel Disease.
Papamichael K; Vande Casteele N; Abraham BP; Ritter T; Jain A; Cheifetz AS
Clin Gastroenterol Hepatol; 2023 Oct; 21(11):2978-2980.e2. PubMed ID: 36372372
[No Abstract] [Full Text] [Related]
38. A Narrative Review on Anti-Tumor Necrosis Factor α Therapies in Inflammatory Bowel Disease During Pregnancy: Immunoglobulin Placental Translocation and its Impact.
Roseira J; Ramos J
Acta Med Port; 2019 Apr; 32(4):305-312. PubMed ID: 31067425
[TBL] [Abstract][Full Text] [Related]
39. Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy.
Miranda-Bautista J; de Gracia-Fernández C; López-Ibáñez M; Barrientos M; Gallo-Moltó A; González-Arias M; González-Gil C; Díaz-Redondo A; Marín-Jiménez I; Menchén L
Dig Dis Sci; 2015 Jul; 60(7):2130-5. PubMed ID: 25680875
[TBL] [Abstract][Full Text] [Related]
40. An update on anti-TNF agents in ulcerative colitis.
Samaan MA; Bagi P; Vande Casteele N; D'Haens GR; Levesque BG
Gastroenterol Clin North Am; 2014 Sep; 43(3):479-94. PubMed ID: 25110254
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
